GLP1R and hepatocellular carcinoma: In one of such retrospective studies, including 1.890.020 diabetic patients, among those with a prior diagnosis of MASLD or MASH, GLP-1 RAs were associated with a significantly lower risk of developing HCC compared to patients under insulin (HR, 0.34; 95% CI, 0.17–0.70), but not compared with other anti-diabetic medications [85].